![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
JB Watkins and CD Klaassen
Valproic acid (VPA) induces an immediate choleresis in the rat which may be attributable to the osmotic properties of VPA-glucuronic acid conjugates in bile. The influence of inducers and inhibitors of glucuronidation of VPA on the biliary excretion and choleretic effect of VPA was studied. Hepatic UDP-glucuronyltransferase activity toward VPA was determined in vitro. Pretreatment with phenobarbital (75 mg/kg/day for 4 days) enhanced VPA glucuronidation; borneol (750 mg/kg) decreased VPA conjugation; 3-methylcholanthrene (20 mg/kg/day for 4 days) and galactosamine (600 mg/kg) had no effect on glucuronidation of VPA in vitro. Hepatic UDP-glucuronic acid content was decreased by borneol and galactosamine administration and was enhanced by phenobarbital and 3-methylcholanthrene pretreatment. The enzyme inducers increased the plasma disappearance of VPA in vivo but did not augment its biliary excretion or choleretic effect. Borneol and galactosamine, which inhibited the conjugation and plasma disappearance of VPA, decreased its biliary excretion and inhibited the VPA-induced increase in bile flow. Thus, the bile flow rate after VPA administration is closely related to the excretion of VPA-glucuronic acid. These data support the conclusion that the choleretic effect of VPA is due to the osmotic activity of VPA conjugates in bile.
This article has been cited by other articles:
|
|
 |
|
  N. J. Patel, M. J. Zamek-Gliszczynski, P. Zhang, Y.-H. Han, P. L. M. Jansen, P. J. Meier, B. Stieger, and K. L. R. Brouwer Phenobarbital Alters Hepatic Mrp2 Function by Direct and Indirect Interactions Mol. Pharmacol., July 1, 2003; 64(1): 154 - 159. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Raymond, M. Fabbro, V. Boige, O. Rixe, M. Frenay, G. Vassal, S. Faivre, E. Sicard, C. Germa, J. M. Rodier, et al. Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naive patients with glioblastoma Ann. Onc., April 1, 2003; 14(4): 603 - 614. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Li, M. P. Grillo, and L. Z. Benet In Vivo Mechanistic Studies on the Metabolic Activation of 2-Phenylpropionic Acid in Rat J. Pharmacol. Exp. Ther., April 1, 2003; 305(1): 250 - 256. [Abstract] [Full Text]
|
|
|
|
 |
|
 D. R. Johnson and C. D. Klaassen Regulation of Rat Multidrug Resistance Protein 2 by Classes of Prototypical Microsomal Enzyme Inducers That Activate Distinct Transcription Pathways Toxicol. Sci., June 1, 2002; 67(2): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. S. Ward, G. M. Pollack, and K. L. R. Brouwer Probenecid-Associated Alterations in Valproic Acid Pharmacokinetics in Rats: Can in Vivo Disposition of Valproate Glucuronide Be Predicted from in Vitro Formation Data? Drug Metab. Dispos., April 13, 2001; 28(12): 1433 - 1439. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
